.png)
Averitas Pharma, a leader in the US for holistic pain management, was formed in 2018 as the US commercial subsidiary of The Grünenthal Group, a global leader in research and development of therapeutics for pain, gout, and inflammation.
The first innovation from Averitas Pharma in the US is QUTENZA® (capsaicin) 8% topical system, a result of acquisitions in 2016 and 2018. These acquisitions gave Grünenthal global commercial rights to QUTENZA and provide Averitas with its first FDA-approved product for distribution.
Discover The QUTENZA Difference by meeting with our team in the Exhibit Hall.
M-QZA-US-02-22-0010
February 2022